Correlating TRIM3 and FoxO1 in tissues with pathological features and prognosis in primary liver cancer patients

Abstract

Abstract: Objective To investigate the association between the expression levels of tripartite motif-containing 3 (TRIM3) and forkhead transcription factor O1 (FoxO1) in tissues, and the pathological characteristics and prognostic implications in patients with primary hepatic carcinoma (PHC). Methods Clinical data from 119 patients with PHC treated at Huaian First Hospital Affiliated to Nanjing Medical University from January 2018 to December 2019 were retrospectively analyzed. The study aimed to compare the expression levels of TRIM3 and FoxO1 in liver cancer tissues and adjacent non-tumorous tissues of these patients. Additionally, The pathological characteristics and prognostic outcomes in patients exhibiting varing expression levels of TRIM3 and FoxO1in their PHC tissues were compared. Results In PHC patients, the expression rates of TRIM3 and FoxO1 in liver cancer tissues(46.22 %, 42.02 % respectively) were significantly lower compared to adjacent non-tumorous tissues((75.63 %, 79.83 % respectively)(P<0.05). Patients with positive TRIM3 expression demonstrated a significantly higher incidence of tumors smaller than 5cm, high differentiation and TNM stages Ⅰ-Ⅱcompared to those with negative TRIM3 expression(P<0.05). Similarly, FoxO1 positive patients showed a significantly higher frequency of tumors smaller than 5 cm, single tumors, and TNM stages Ⅰ-Ⅱ compared to FoxO1 negative patients (P<0.05). The 3-year survival rates for patients with positive TRIM3 expression(61.82%) were notably higher than those with negative expression(31.25 %), with a statistically significant difference(Log Rank=10.242, P=0.001). Likewise, the 3-year survival rates were 60.00 % in FoxO1-positive patients and 34.78 % in FoxO1-negative patients, making a significant difference(Log Rank=6.978, P=0.008). Conclusion The expression levels of TRIM3 and FoxO1 in tissues demonstrate a substantial association with both the pathological attributes and the prognostic outlook of PHC patients, indicating their potential as vital prognostic biomarkers for evaluating patint status and predicting clinical outcomes in PHC.

Key words: Tripartite motif-containing 3, Forkhead transcription factor O1, Primary hepatic carcinoma, Pathological features, Prognosis

ZHANG Li-li, ZHEN Fei. Correlating TRIM3 and FoxO1 in tissues with pathological features and prognosis in primary liver cancer patients[J]. Chinese Hepatolgy, 2024, 29(1): 95-98.

References

[1] Mao JX, Teng F, Sun KY, et al. Two-in-one: A pooled analysis of primary hepatic neuroendocrine carcinoma combine d/collide d with hepatocellular carcinoma[J]. Hepatol Pancreat Dis,2020,19(4):399-403.
[2] Li CC, Zhang YL, Zheng YL. Effectiveness and Safety of Chinese Medicine in the Treatment of PostTACE Syndrome of Primary Hepatocellular Carcinoma: A Systematic Review[J]. Journal of Hainan Medical University,2022, 28(18):38-52.
[3] Ray SK, Mukherjee S. Altered Expression of TRIM Proteins-Inimical Outcome and Inimitable Oncogenic Function in Breast Cancer with Diverse Carcinogenic Hallmarks[J]. Curr Mol Med,2023,23(1):44-53.
[4] Kar A, Kumari K, Mishra S K, et al. Self-assembled DNA nanostructure containing oncogenic miRNA-mediated cell proliferation by downregulation of FOXO1 expression[J]. BMC cancer,2022, 22(1):1332-1332.
[5] 中国抗癌协会肝癌专业委员会, 中华医学会肝病学分会肝癌学组, 中国抗癌协会病理专业委员会, 等. 原发性肝癌规范化病理诊断指南(2015年版)[J]. 中华肝脏病杂志,2015,23(5):321-327.
[6] 谭国钳, 王洋, 吴帆. 肝癌组织中EGFL9基因的表达及其对Huh-7肝癌细胞系增殖、侵袭和迁移的影响[J]. 现代肿瘤医学,2022,30(7):1179-1184.
[7] 刘旭初, 覃世运, 陈丽君, 等. KRAS基因突变对经肝动脉化疗栓塞术治疗的中晚期原发性肝癌患者预后的预测价值[J]. 临床肝胆病杂志,2022,38(11):2514-2519.
[8] Zhu J, Wu G, Ke Z, et al. Targeting TRIM3 deletion-induced tumorassociated lymphangiogenesis prohibits lymphatic metastasis in esophageal squamous cell carcinoma[J]. Oncogene,2019,38(15):2736-2749.
[9] 高海宁, 白瑞霞, 赵鹏伟, 等. miR-581调控FOXO1对卵巢癌SKOV3细胞自噬的影响[J]. 肿瘤防治研究,2022,49(5):403-407.
[10] 田秀芳, 陈红晓, 栾雅静, 等. 子宫内膜癌组织中miR-96、FOXO1表达变化及意义[J]. 山东医药,2021,61(31):1-4.
[11] 从雨, 徐娟. TRIM3在肿瘤中的研究进展[J]. 临床与病理杂志,2020,40(3):728-733.
[12] 王琪, 廖振蓉, 罗德平, 等. TRIM19通过调控p53信号促进卵巢癌进展的作用及机制研究[J]. 中国免疫学杂志,2022,38(1):51-55.
[13] 张志红, 朱真如, 盛海龙, 等. TRIM21可抑制肝癌细胞的侵袭能力:基于泛素化途径降解β-catenin[J]. 南方医科大学学报,2022,42(1):55-62.
[14] 郭旭辉, 张敬洋, 焦得闯, 等. 三重基序蛋白24在乳腺癌中的表达及临床意义[J]. 中华实验外科杂志,2020,37(2):313-316.
[15] 陈洁, 耿慧武, 王凤杰, 等. FoxO1蛋白在癌细胞质中的差异表达及其功能研究[J]. 安徽医科大学学报,2021,56(12):1847-1852.
[16] 门婧睿, 谭建军, 孙洪亮. 肝癌预后miRNA风险评分模型的鉴定和分析[J]. 生物化学与生物物理进展,2020,47(4):344-360.
[17] Huang XQ, Zhang XF, Xia JH, et al. Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer[J]. Chin J Cancer,2017,36(1):77-77.
[18] 吴蓓, 高春辉, 陶连元, 等. FoxO1蛋白在原发性肝癌(PHC)组织中的表达及与对预后的影响[J]. 实用癌症杂志,2021,36(6):899-902.
[19] 赵强, 陈文娟, 韩乐, 等. 长链非编码RNA FOXO1在肝癌中的表达及意义[J]. 现代生物医学进展,2018,18(24):4712-4715.
[20] 姜靖雯, 陈学武, 罗荣城, 等. 三氟拉嗪激活FOXO1相关的Bax/Bcl-2信号通道诱导肝癌细胞凋亡[J]. 中国药学杂志,2019,54(11):886-893.